On 16 February 2006, orphan designation (EU/3/06/349) was granted by the European Commission to Vectura Group plc, United Kingdom, for apomorphine hydrochloride (inhalation use) for the treatment of off-periods in Parkinson's disease not responding to oral treatment.
The sponsorship was transferred to Vectura Ireland Limited, Ireland in March 2019.
Treatment of off-periods in Parkinson's disease not responding to oral treatment
|Orphan designation status||
|EU designation number||
|Date of designation||
|February 2023||The sponsor’s address was updated.|
Documents related to this orphan designation evaluation
EU/3/06/349: Public summary of positive opinion for orphan designation of apomorphine hydrochloride (inhalation use) for the treatment of off-periods in Parkinson’s disease not responding to oral treatment (PDF/130.36 KB)
First published: 24/08/2006
Last updated: 24/08/2006
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: